75 results on '"Fischer Q"'
Search Results
2. Impact of mitral annulus calcification and associated mitral stenosis on clinical outcomes of transcatheter aortic valve replacement
- Author
-
Mesnier, J., primary, Urena-Alcazar, M., additional, Chong-Nguyen, C., additional, Fischer, Q., additional, Carrasco, J.L., additional, Terzian, Z., additional, Brochet, E., additional, Iung, B., additional, and Himbert, D., additional
- Published
- 2021
- Full Text
- View/download PDF
3. Impact of mitral annular calcification associated mitral stenosis on clinical outcomes in patients undergoing transcatheter aortic valve implantation
- Author
-
Mesnier, J, primary, Urena, M, additional, Nguyen, C, additional, Carrasco, J.L, additional, Terzian, Z, additional, Fischer, Q, additional, Brochet, E, additional, Iung, I, additional, and Himbert, D, additional
- Published
- 2020
- Full Text
- View/download PDF
4. Transcatheter valve-in-valve or valve-in-ring mitral valve implantation in young women contemplating pregnancy
- Author
-
Fuchs, A., primary, Urena Alcazar, M., additional, Nguyen, C., additional, Brochet, E., additional, Abtan, J., additional, Fischer, Q., additional, Ducrocq, G., additional, Iung, B., additional, Vahanian, A., additional, and Himbert, D., additional
- Published
- 2020
- Full Text
- View/download PDF
5. Outcomes of transcatheter aortic-valve implantation in patients receiving chronic systemic corticosteroid treatment
- Author
-
Gautier, A., primary, Urena, M., additional, Brochet, E., additional, Fischer, Q., additional, Abtan, J., additional, Nguyen, C., additional, Carrasco, J.L., additional, Iung, B., additional, and Himbert, D., additional
- Published
- 2020
- Full Text
- View/download PDF
6. Impact of Pre-Existing Left Bundle Branch Block in Transcatheter Aortic Valve Replacement Recipients
- Author
-
Fischer, Q., primary, Himbert, D., additional, Webb, J., additional, Eltchaninoff, Hélène., additional, Muñoz-García, A.J., additional, Tamburino, C., additional, Nombela-Franco, L., additional, Nietlispach, F., additional, Philippon, F., additional, Urena, M., additional, and Rodés-Cabau, J., additional
- Published
- 2019
- Full Text
- View/download PDF
7. P2681Long-term outcomes after percutaneous coronary intervention for stable coronary artery disease versus acute coronary syndromes
- Author
-
Helft, G, primary, Maupain, C, additional, Fischer, Q, additional, Sharma, A, additional, Barthelemy, O, additional, Hammoudi, N, additional, Berman, E, additional, Hage, G, additional, Zeitouni, M, additional, Silvain, J, additional, and Le Feuvre, C, additional
- Published
- 2018
- Full Text
- View/download PDF
8. P283Could social media improve students knowledge in cardiology?
- Author
-
Fischer, Q, primary, Nhan, P, additional, Picard, F, additional, and Varenne, O, additional
- Published
- 2018
- Full Text
- View/download PDF
9. How to improve medical students’ knowledge using a social network?
- Author
-
Fischer, Q., primary, Nhan, P., additional, Sbissa, Y., additional, Adjedj, J., additional, Sochala, M., additional, Durand Viel, G., additional, Kanellopoulos, G., additional, Picard, F., additional, Fanon, L., additional, and Varenne, O., additional
- Published
- 2018
- Full Text
- View/download PDF
10. Can simulator-based teaching improve medical students’ knowledge and competences? Results of a randomized trial using a coronary angiography simulator to learn coronary anatomy
- Author
-
Fischer, Q., primary, Sbissa, Y., additional, Nhan, P., additional, Adjedj, J., additional, and Varenne, O., additional
- Published
- 2018
- Full Text
- View/download PDF
11. 2866Optimal long-term antithrombotic treatment of patients with stable coronary artery disease and atrial fibrillation: OLTAT registry
- Author
-
Fischer, Q., primary, Georges, J.L., additional, Le Feuvre, C., additional, Berman, E., additional, Cohen, S., additional, Jolivet, I., additional, and Helft, G., additional
- Published
- 2017
- Full Text
- View/download PDF
12. P5426Obstructive prosthesis caused by valvular pannus: characteristics and diagnostic strategy, about 71 cases
- Author
-
Alos, B., primary, Bouleti, C.B., additional, Fischer, Q., additional, Garcia, R., additional, and Vahanian, A., additional
- Published
- 2017
- Full Text
- View/download PDF
13. Aortic prosthetic heart valve obstruction caused by pannus: characteristics and diagnostic strategy, about a 71 patients multicentric study
- Author
-
Alos, B., primary, Bouleti, C., additional, Fischer, Q., additional, Garcia, R., additional, Iung, B., additional, Raffoul, R., additional, Brochet, E., additional, Jayle, C., additional, Leprince, P., additional, Nataf, P., additional, and Vahanian, A., additional
- Published
- 2017
- Full Text
- View/download PDF
14. Optimal long-term antithrombotic treatment of patients with stable coronary artery disease and atrial fibrillation: OLTAT registry
- Author
-
Fischer, Q., primary, Helft, G., additional, Collet, J.P., additional, Berman, E., additional, Cohen, S., additional, Jolivet, I., additional, Laveau, F., additional, and Le Feuvre, C., additional
- Published
- 2017
- Full Text
- View/download PDF
15. Modelling Permeability in Rotliegend Gas Sandstones from NMR
- Author
-
Fabricius, I.L., primary, Rosenbrand, E., additional, Fischer, Q., additional, and Grattoni, C., additional
- Published
- 2015
- Full Text
- View/download PDF
16. DER EINFLUSS VERSCHIEDENER SALZKONZENTRATIONEN AUF DIE HÄMAGGLUTINATION
- Author
-
FORSSMAN, J., primary, WADSTEIN, TH., additional, and FISCHER, Q., additional
- Published
- 2010
- Full Text
- View/download PDF
17. Adult visual experience promotes recovery of primary visual cortex from long-term monocular deprivation
- Author
-
Fischer, Q. S., primary, Aleem, S., additional, Zhou, H., additional, and Pham, T. A., additional
- Published
- 2007
- Full Text
- View/download PDF
18. DER EINFLUSS VERSCHIEDENER SALZKONZENTRATIONEN AUF DIE HÄMAGGLUTINATION.
- Author
-
FORSSMAN, J., WADSTEIN, TH., and FISCHER, Q.
- Published
- 1930
- Full Text
- View/download PDF
19. Secondary Femoral Access Hemostasis During Transcatheter Aortic Valve Replacement: Impact of Vascular Closure Devices
- Author
-
Junquera, L., Marina Urena, Muñoz-Garcia, A., Nombela-Franco, L., Faurie, B., Veiga-Fernandez, G., Alperi, A., Serra, V., Fischer, Q., Himbert, D., Muñoz-García, E., Vera-Urquiza, R., Jiménez-Quevedo, P., La Torre Hernandez, J. M., Pascual, I., Garcia Del Blanco, B., Mohammadi, S., Faroux, L., Couture, T., Côté, M., and Rodés-Cabau, J.
- Subjects
Aged, 80 and over ,Femoral Artery ,Transcatheter Aortic Valve Replacement ,Hemostasis ,Treatment Outcome ,Hemostatic Techniques ,Aortic Valve ,Humans ,Vascular Closure Devices ,Aged - Abstract
Vascular and bleeding complications related to secondary femoral access site are frequent in patients undergoing transcatheter aortic valve replacement (TAVR), and their occurrence is associated to poorer outcomes. We aimed to evaluate the clinical impact of vascular closure devices (VCDs) for secondary femoral access hemostasis in TAVR procedures.This was a multicenter study including 4031 patients who underwent TAVR (mean age, 81 ± 8 years; mean Society of Thoracic Surgeons [STS] score, 4.9 [interquartile range, 3.3-7.6]), and had a secondary femoral access. The 30-day clinical outcomes were analyzed according to femoral access-site hemostasis (manual compression vs VCD), and according to the type of VCD (Perclose [Abbott Cardiovascular] vs Angio-Seal [Terumo Interventional Systems]) using a propensity-matched, multivariable, logistic regression model.Manual compression was used in 941 patients (23.3%) and VCDs were used in 3090 patients (76.7%; Perclose in 1549 patients [38.4%] and Angio-Seal in 1541 patients [38.2%]) for secondary femoral access hemostasis. Vascular complications related to secondary access site occurred in 162 patients (4%), and were more frequent in patients who underwent manual compression (7.2%) compared with VCD hemostasis (3%; adjusted P.001). In the VCD group, the use of Angio-Seal (vs Perclose) was associated with a higher rate of vascular complications (3.7% vs 2.4%, respectively; adjusted P=.02), femoral artery pseudoaneurysm (1.3% vs 0.4%, respectively; adjusted P.01), invasive treatment requirement for treating vascular complications (surgery: 0.8% vs 0.3%, respectively [adjusted P=.03]; and thrombin injection: 0.9% vs 0%, respectively [adjusted P.001]).VCDs represented a safer and more effective alternative compared with manual compression for secondary femoral access-site hemostasis in patients undergoing TAVR procedures, and the Perclose VCD was associated with the lowest risk of vascular complications. Future randomized studies are warranted.
20. 439 - Aortic prosthetic heart valve obstruction caused by pannus: characteristics and diagnostic strategy, about a 71 patients multicentric study.
- Author
-
Alos, B., Bouleti, C., Fischer, Q., Garcia, R., Iung, B., Raffoul, R., Brochet, E., Jayle, C., Leprince, P., Nataf, P., and Vahanian, A.
- Published
- 2017
- Full Text
- View/download PDF
21. 237 - Optimal long-term antithrombotic treatment of patients with stable coronary artery disease and atrial fibrillation: OLTAT registry.
- Author
-
Fischer, Q., Helft, G., Collet, J.P., Berman, E., Cohen, S., Jolivet, I., Laveau, F., and Le Feuvre, C.
- Published
- 2017
- Full Text
- View/download PDF
22. Impact of Preexisting Left Bundle Branch Block in Transcatheter Aortic Valve Replacement Recipients
- Author
-
Marina Urena, Josep Rodés-Cabau, Antonio J. Muñoz-García, Bruno García del Blanco, Corrado Tamburino, Luis Nombela-Franco, Eric Durand, Vicenç Serra, Claire Bouleti, Asim N. Cheema, Dominique Himbert, Quentin Fischer, Eric Dumont, Alexandre Abizaid, François Philippon, César Morís, Henrique Barbosa Ribeiro, John G. Webb, Marc Ruel, Fabian Nietlispach, Hélène Eltchaninoff, Marco Barbanti, Luis M. Benitez, Ignacio J. Amat-Santos, Antonio Dager, Sebastiano Immè, Mélanie Côté, Juan H. Alonso Briales, Raquel del Valle, Francesco Maisano, Rogério Sarmento-Leite, Fabio Sandoli de Brito, Fischer, Q, Himbert, D, Webb, Jg, Eltchaninoff, H, Munoz-Garcia, Aj, Tamburino, C, Nombela-Franco, L, Nietlispach, F, Moris, C, Ruel, M, Dager, Ae, Serra, V, Cheema, An, Amat-Santos, Ij, de Brito, F, Ribeiro, H, Abizaid, A, Sarmento-Leite, R, Dumont, E, Barbanti, M, Durand, E, Alonso Briales, Jh, Bouleti, C, Imme, S, Maisano, F, Del Valle, R, Miguel Benitez, L, Garcia Del Blanco, B, Cote, M, Philippon, F, Urena, M, and Rodes-Cabau, J
- Subjects
Aortic valve ,Male ,medicine.medical_specialty ,Canada ,Pacemaker, Artificial ,Time Factors ,Transcatheter aortic ,medicine.medical_treatment ,Bundle-Branch Block ,Heart Valve Diseases ,030204 cardiovascular system & hematology ,Risk Assessment ,Transcatheter Aortic Valve Replacement ,03 medical and health sciences ,cause of death ,Electrocardiography ,0302 clinical medicine ,Postoperative Complications ,Valve replacement ,Risk Factors ,Internal medicine ,medicine ,echocardiography ,Humans ,030212 general & internal medicine ,Cause of death ,Aged ,Aged, 80 and over ,Bundle branch block ,business.industry ,Left bundle branch block ,Follow up studies ,Cardiac Pacing, Artificial ,medicine.disease ,aortic valve ,follow-up studies ,Europe ,medicine.anatomical_structure ,Treatment Outcome ,Echocardiography ,Aortic Valve ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business ,Brazil - Abstract
Background: The impact of preexisting left bundle branch block (LBBB) in transcatheter aortic valve replacement (TAVR) recipients is unknown. The aim of this study was to determine the impact of preexisting LBBB on clinical outcomes after TAVR. Methods and Results: This multicenter study evaluated 3404 TAVR candidates according to the presence or absence of LBBB on baseline ECG. TAVR complications and causes of death were defined according to Valve Academic Research Consortium-2 definitions. Follow-up outpatient visits or telephone interviews were conducted at 30 days, 12 months, and yearly thereafter. Echocardiography examinations were performed at baseline, at hospital discharge, and at 1-year follow-up. Preexisting LBBB was present in 398 patients (11.7%) and was associated with an increased risk of permanent pacemaker implantation (PPI; 21.1% versus 14.8%; adjusted odds ratio, 1.51; 95% CI, 1.12–2.04) but not death (7.3% versus 5.5%; adjusted odds ratio, 1.33; 95% CI, 0.84–2.12) at 30 days. At a mean follow-up of 22±21 months, there were no differences between patients with and without preexisting LBBB in overall mortality (adjusted hazard ratio, 0.94; 95% CI, 0.75–1.18) and cardiovascular mortality (adjusted hazard ratio, 0.90; 95% CI, 0.68–1.21). In a subanalysis of 2421 patients without PPI at 30 days and with complete follow-up about the PPI, preexisting LBBB was not associated with an increased risk of PPI or sudden cardiac death. Patients with preexisting LBBB had a lower left ventricular ejection fraction (LVEF) at baseline and at 1-year follow-up ( P P =0.327). Conclusions: Preexisting LBBB significantly increased the risk of early (but not late) PPI after TAVR, without any significant effect on overall mortality or cardiovascular mortality. Preexisting LBBB was associated with lower LVEF pre-TAVR but did not prevent an increase in LVEF post-TAVR similar to patients without LBBB.
- Published
- 2018
23. Antiplatelet therapy for treatment of coronary artery disease in older patients.
- Author
-
Fischer Q, Pham V, Seret G, Brami P, Picard F, and Varenne O
- Subjects
- Humans, Aged, Risk Factors, Treatment Outcome, Age Factors, Risk Assessment, Aged, 80 and over, Male, Clinical Decision-Making, Female, Dual Anti-Platelet Therapy adverse effects, Platelet Aggregation Inhibitors adverse effects, Platelet Aggregation Inhibitors therapeutic use, Coronary Artery Disease therapy, Coronary Artery Disease drug therapy, Hemorrhage chemically induced, Percutaneous Coronary Intervention adverse effects
- Abstract
Coronary artery disease in older patients is more frequently diffuse and complex, and is often treated by percutaneous coronary intervention on top of medical therapy. There are currently no specific recommendations for antiplatelet therapy in patients aged≥75 years. Aspirin remains pivotal, and is still indicated as a long-term treatment after percutaneous coronary intervention. In addition, a P2Y
12 inhibitor is administered for 6-12 months according to clinical presentation. Age is a minor bleeding risk factor, but because older patients often have several co-morbidities, they are considered as having a high bleeding risk according to different scoring systems. This increased bleeding risk has resulted in different therapeutic strategies for antithrombotic treatment after percutaneous coronary intervention; these include short dual antiplatelet therapy, a switch from potent to less potent antiplatelet therapy or single antiplatelet therapy with a P2Y12 inhibitor instead of aspirin, among others. A patient-centred approach, taking into account health status, functional ability, frailty, cognitive skills, bleeding and ischaemic risks and patient preference, is essential when caring for older adults with coronary artery disease. The present review focuses on the knowledge base, specificities of antiplatelet therapies, a balance between haemorrhagic and ischaemic risk, strategies for antiplatelet therapy and directions for future investigation pertaining to coronary artery disease in older patients., (Copyright © 2024 Elsevier Masson SAS. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
24. Clinical impact of complex percutaneous coronary intervention in the pre-TAVR workup.
- Author
-
Avvedimento M, Campelo-Parada F, Nombela-Franco L, Fischer Q, Donaint P, Serra V, Veiga G, Gutiérrez E, Franzone A, Vilalta V, Alperi A, Regueiro A, Asmarats L, B Ribeiro H, Matta A, Muñoz-García A, Tirado G, Urena M, Metz D, Rodenas-Alesina E, de la Torre Hernández JM, Angellotti D, Fernández-Nofrerías E, Pascual I, Vidal-Calés P, Arzamendi D, Carter Campanha-Borges D, Hoang Trinh K, Nuche J, Côté M, Faroux L, and Rodés-Cabau J
- Abstract
Introduction and Objectives: In patients undergoing percutaneous coronary intervention (PCI) in the workup pre-transcatheter aortic valve replacement (TAVR), the clinical impact of coronary revascularization complexity remains unknown. This study sought to examine the impact of PCI complexity on clinical outcomes after TAVR in patients undergoing PCI in the preprocedural workup., Methods: This was a multicenter study including consecutive patients scheduled for TAVR with concomitant significant coronary artery disease. Complex PCI was defined as having at least 1 of the following features: 3 vessels treated, ≥ 3 stents implanted, ≥ 3 lesions treated, bifurcation with 2 stents implanted, total stent length >60mm, or chronic total occlusion. The rates of major adverse cardiac events (MACE), including cardiovascular mortality, myocardial infarction, and coronary revascularization were evaluated., Results: A total of 1550 patients were included, of which 454 (29.3%) underwent complex PCI in the pre-TAVR workup. After a median follow-up period of 2 [1-3] years after TAVR, the incidence of MACE was 9.6 events per 100 patients-years. Complex PCI significantly increased the risk of cardiac death (HR, 1.44; 95%CI, 1.01-2.07), nonperiprocedural myocardial infarction (HR, 1.52; 95%CI, 1.04-2.21), and coronary revascularization (HR, 2.46; 95%CI, 1.44-4.20). In addition, PCI complexity was identified as an independent predictor of MACE after TAVR (HR, 1.31; 95%CI, 1.01-1.71; P=.042)., Conclusions: In TAVR candidates with significant coronary artery disease requiring percutaneous treatment, complex revascularization was associated with a higher risk of MACE. The degree of procedural complexity should be considered a strong determinant of prognosis in the PCI-TAVR population., (Copyright © 2024 Sociedad Española de Cardiología. Published by Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
25. Evolution of Coronary Stent Platforms: A Brief Overview of Currently Used Drug-Eluting Stents.
- Author
-
Brami P, Fischer Q, Pham V, Seret G, Varenne O, and Picard F
- Abstract
Cardiovascular disease, including ischemic heart disease, is the leading cause of death worldwide, and percutaneous coronary interventions (PCIs) have been demonstrated to improve the prognosis of these patients on top of optimal medical therapy. PCIs have evolved from plain old balloon angioplasty to coronary stent implantation at the end of the last century. There has been a constant technical and scientific improvement in stent technology from bare metal stents to the era of drug-eluting stents (DESs) to overcome clinical challenges such as target lesion failure related to in-stent restenosis or stent thrombosis. A better understanding of the underlying mechanisms of these adverse events has led DESs to evolve from first-generation DESs to thinner and ultrathin third-generation DESs with improved polymer biocompatibility that seems to have reached a peak in efficiency. This review aims to provide a brief historical overview of the evolution of coronary DES platforms and an update on clinical studies and major characteristics of the most currently used DESs.
- Published
- 2023
- Full Text
- View/download PDF
26. Late Bleeding Events in Patients Undergoing Percutaneous Coronary Intervention in the Workup Pre-TAVR.
- Author
-
Avvedimento M, Campelo-Parada F, Munoz-Garcia E, Nombela-Franco L, Fischer Q, Donaint P, Serra V, Veiga G, Gutiérrez E, Esposito G, Vilalta V, Alperi A, Regueiro A, Asmarats L, Ribeiro HB, Matta A, Munoz-Garcia A, Tirado-Conte G, Urena M, Metz D, Rodenas-Alesina E, de la Torre Hernandez JM, Fernandez-Nofrerias E, Pascual I, Vidal-Cales P, Arzamendi D, Campanha-Borges DC, Trinh KH, Côté M, Faroux L, and Rodés-Cabau J
- Subjects
- Humans, Female, Aged, Aged, 80 and over, Male, Treatment Outcome, Hemorrhage chemically induced, Catheters, Percutaneous Coronary Intervention adverse effects, Transcatheter Aortic Valve Replacement adverse effects
- Abstract
Background: In patients undergoing percutaneous coronary intervention (PCI) in the work-up pre-transcatheter aortic valve replacement (TAVR), the incidence and clinical impact of late bleeding events (LBEs) remain largely unknown., Objectives: This study sought to determine the incidence, clinical characteristics, associated factors, and outcomes of LBEs in patients undergoing PCI in the work-up pre-TAVR., Methods: This was a multicenter study including 1,457 consecutive patients (mean age 81 ± 7 years; 41.5% women) who underwent TAVR and survived beyond 30 days. LBEs (>30 days post-TAVR) were defined according to the Valve Academic Research Consortium-2 criteria., Results: LBEs occurred in 116 (7.9%) patients after a median follow-up of 23 (IQR: 12-40) months. Late bleeding was minor, major, and life-threatening or disabling in 21 (18.1%), 63 (54.3%), and 32 (27.6%) patients, respectively. Periprocedural (<30 days post-TAVR) major bleeding and the combination of antiplatelet and anticoagulation therapy at discharge were independent factors associated with LBEs (P ≤ 0.02 for all). LBEs conveyed an increased mortality risk at 4-year follow-up compared with no bleeding (43.9% vs 36.0; P = 0.034). Also, LBE was identified as an independent predictor of all-cause mortality after TAVR (HR: 1.39; 95% CI: 1.05-1.83; P = 0.020)., Conclusions: In TAVR candidates with concomitant significant coronary artery disease requiring percutaneous treatment, LBEs after TAVR were frequent and associated with increased mortality. Combining antiplatelet and anticoagulation regimens and the occurrence of periprocedural bleeding determined an increased risk of LBEs. Preventive strategies should be pursued for preventing late bleeding after TAVR, and further studies are needed to provide more solid evidence on the most safe and effective antithrombotic regimen post-TAVR in this challenging group of patients., Competing Interests: Funding Support and Author Disclosures Dr Rodés-Cabau holds the Research Chair “Fondation Famille Jacques Larivière” for the Development of Structural Heart Disease Interventions (Laval University); and has received institutional research grants and speaker/consultant fees from Edwards Lifesciences and Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
27. Obstructive valve thrombosis after transcatheter aortic valve replacement (TAVR) in Sneddon syndrome without antiphospholipid antibodies.
- Author
-
Giovachini L, Pham V, Picard F, and Fischer Q
- Subjects
- Female, Humans, Catheters, Antibodies, Antiphospholipid, Anticoagulants, Fibrinolytic Agents, Transcatheter Aortic Valve Replacement, Sneddon Syndrome, Thrombosis
- Abstract
We study a case of early obstructive leaflet thrombosis following a transcatheter aortic valve replacement (TAVR) in a woman in her 50s with a history of Sneddon syndrome treated by antiplatelet therapy. The thrombosis regressed following the use of vitamin K antagonists (VKA) for 6 weeks. Subacute TAVR leaflet thrombosis reappeared after discontinuation of VKA use. The main takeaways of this study were the detection of high-risk patients that could benefit from systematic post-TAVR anticoagulation and the early diagnosis of obstructive leaflet thrombosis associated with elevated transvalvular gradient, whose management differs from that of subclinical leaflet thrombosis., Competing Interests: Competing interests: None declared., (© BMJ Publishing Group Limited 2023. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
28. Intracoronary imaging in addition to coronary angiography for patients with out-of-hospital cardiac arrest: More information for better care?
- Author
-
Brami P, Picard F, Seret G, Fischer Q, Pham V, and Varenne O
- Subjects
- Humans, Coronary Angiography adverse effects, Prognosis, Electrocardiography, Out-of-Hospital Cardiac Arrest diagnostic imaging, Out-of-Hospital Cardiac Arrest therapy, Coronary Occlusion, Percutaneous Coronary Intervention adverse effects
- Abstract
About 70% of out-of-hospital cardiac arrests are related to an ischaemic heart disease in Western countries. Percutaneous coronary intervention has been shown to improve the prognosis of survivors when an unstable coronary lesion is identified as the potential cause of the cardiac arrest. Acute complete coronary occlusion is often demonstrated among patients with ST-segment elevation on electrocardiogram after the return of spontaneous circulation. In patients without ST-segment elevation, routine coronary angiography has been shown to be not superior to conservative management. However, an electrocardiogram-based decision to perform immediate coronary angiography could be insufficient to identify unstable coronary lesions, which are frequently associated with intermediate coronary stenosis. Intracoronary imaging can be helpful to detect plaque rupture or erosion and intracoronary thrombus, but could also lead to better stent implantation, and help to reduce the risk of stent thrombosis. In patients with coronary lesions without the instability characteristic, conservative management should be the default strategy, and a search for another cause of the cardiac arrest should be systematic. In the present review, we sought to describe the potential benefit of intracoronary imaging in patients with out-of-hospital cardiac arrest., (Copyright © 2023 Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
29. Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Complex Coronary Artery Disease.
- Author
-
Alperi A, Mohammadi S, Campelo-Parada F, Munoz-Garcia E, Nombela-Franco L, Faroux L, Veiga G, Serra V, Fischer Q, Pascual I, Asmarats L, Gutiérrez E, Regueiro A, Vilalta V, Ribeiro HB, Matta A, Munoz-Garcia A, Armijo G, Metz D, De la Torre Hernandez JM, Rodenas-Alesina E, Urena M, Moris C, Arzamendi D, Perez-Fuentes P, Fernandez-Nofrerias E, Campanha-Borges DC, Mesnier J, Voisine P, Dumont E, Kalavrouziotis D, and Rodés-Cabau J
- Subjects
- Aortic Valve diagnostic imaging, Aortic Valve surgery, Humans, Risk Factors, Treatment Outcome, Aortic Valve Stenosis complications, Aortic Valve Stenosis diagnostic imaging, Aortic Valve Stenosis surgery, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease surgery, Heart Valve Prosthesis Implantation adverse effects, Percutaneous Coronary Intervention adverse effects, Transcatheter Aortic Valve Replacement adverse effects
- Abstract
Objectives: The aim of this study was to compare, in a cohort of patients with complex coronary artery disease (CAD) and severe aortic stenosis (AS), the clinical outcomes associated with transfemoral transcatheter aortic valve replacement (TAVR) (plus percutaneous coronary intervention [PCI]) versus surgical aortic valve replacement (SAVR) (plus coronary artery bypass grafting [CABG])., Background: Patients with complex CAD were excluded from the main randomized trials comparing TAVR with SAVR, and no data exist comparing TAVR + PCI vs SAVR + CABG in such patients., Methods: A multicenter study was conducted including consecutive patients with severe AS and complex CAD (SYNTAX [Synergy Between PCI with Taxus and Cardiac Surgery] score >22 or unprotected left main disease). A 1:1 propensity-matched analysis was performed to account for unbalanced covariates. The rates of major adverse cardiac and cerebrovascular events (MACCE), including all-cause mortality, nonprocedural myocardial infarction, need for new coronary revascularization, and stroke, were evaluated., Results: A total of 800 patients (598 undergoing SAVR + CABG and 202 undergoing transfemoral TAVR + PCI) were included, and after propensity matching, a total of 156 pairs of patients were generated. After a median follow-up period of 3 years (interquartile range: 1-6 years), there were no significant differences between groups for MACCE (HR for transfemoral TAVR vs SAVR: 1.33; 95% CI: 0.89-1.98), all-cause mortality (HR: 1.25; 95% CI: 0.81-1.94), myocardial infarction (HR: 1.16; 95% CI: 0.41-3.27), and stroke (HR: 0.42; 95% CI: 0.13-1.32), but there was a higher rate of new coronary revascularization in the TAVR + PCI group (HR: 5.38; 95% CI: 1.73-16.7)., Conclusions: In patients with severe AS and complex CAD, TAVR + PCI and SAVR + CABG were associated with similar rates of MACCE after a median follow-up period of 3 years, but TAVR + PCI recipients exhibited a higher risk for repeat coronary revascularization. Future trials are warranted., Competing Interests: Funding Support and Author Disclosures Dr Alperi was supported by a research grant from the Martín Escudero Foundation. Dr Rodés-Cabau holds the Research Chair “Fondation Famille Jacques Larivière” for the Development of Structural Heart Disease Interventions; and has received institutional research grants from Edwards Lifesciences and Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
30. Impact of Mitral Annular Calcium and Mitral Stenosis on Outcomes After Transcatheter Aortic Valve Implantation.
- Author
-
Mesnier J, Urena M, Chong-Nguyen C, Fischer Q, Kikoïne J, Carrasco JL, Terzian Z, Brochet E, Iung B, and Himbert D
- Subjects
- Aged, 80 and over, Aortic Valve Stenosis metabolism, Aortic Valve Stenosis surgery, Echocardiography, Female, Follow-Up Studies, Humans, Male, Mitral Valve metabolism, Mitral Valve Stenosis complications, Mitral Valve Stenosis diagnosis, Prognosis, Retrospective Studies, Risk Factors, Severity of Illness Index, Aortic Valve Stenosis complications, Calcium metabolism, Mitral Valve diagnostic imaging, Mitral Valve Stenosis surgery, Transcatheter Aortic Valve Replacement methods
- Abstract
Mitral annular calcium (MAC) is a common finding in patients undergoing transcatheter aortic valve implantation (TAVI) and may be associated with mitral stenosis (MAC-MS). Their impact on post-TAVI outcomes remains controversial. We sought to assess the impact of MAC and MAC-MS on clinical outcomes following TAVI. We included 1,177 patients who consecutively underwent TAVI in our institution between January 2008 and May 2018. MAC diagnosis reposed on echocardiogram and computed tomography. The combination of MAC and a mean transmitral gradient ≥ 5 mmHg defined MAC-MS. The study included 1,177 patients, of whom 504 (42.8%) had MAC and 85 (7.2%) had MAC-MS. Patients with and without MAC had similar outcomes except for a higher rate of pacemaker implantation in MAC patients (adjusted HR: 1.32, 95% CI: 1.03-1.69, p = 0.03). The subgroup of patients with severe MAC had similar outcomes. However, MAC-MS was an independent predictor of all-cause mortality at 30 days (adjusted HR: 2.30, 95% CI: 1.08-4.86, p = 0.03) and 1 year (adjusted HR: 1.73, 95% CI: 1.04-2.89, p = 0.04). In conclusion, MAC is present in nearly half of the patients treated with TAVI but MAC-MS is far less frequent. In itself, even severe, MAC does not influence outcomes while MAC-MS is an independent predictor of all-cause 1-year mortality. Measurement of mean transmitral gradient identifies patients with MAC at high risk after TAVI., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
31. Secondary Femoral Access Hemostasis During Transcatheter Aortic Valve Replacement: Impact of Vascular Closure Devices.
- Author
-
Junquera L, Urena M, Muñoz-Garcia A, Nombela-Franco L, Faurie B, Veiga-Fernandez G, Alperi A, Serra V, Fischer Q, Himbert D, Muñoz-García E, Vera-Urquiza R, Jiménez-Quevedo P, de la Torre Hernandez JM, Pascual I, Garcia Del Blanco B, Mohammadi S, Faroux L, Couture T, Côté M, and Rodés-Cabau J
- Subjects
- Aged, Aged, 80 and over, Aortic Valve diagnostic imaging, Aortic Valve surgery, Femoral Artery surgery, Hemostasis, Hemostatic Techniques, Humans, Treatment Outcome, Transcatheter Aortic Valve Replacement, Vascular Closure Devices
- Abstract
Background: Vascular and bleeding complications related to secondary femoral access site are frequent in patients undergoing transcatheter aortic valve replacement (TAVR), and their occurrence is associated to poorer outcomes. We aimed to evaluate the clinical impact of vascular closure devices (VCDs) for secondary femoral access hemostasis in TAVR procedures., Methods: This was a multicenter study including 4031 patients who underwent TAVR (mean age, 81 ± 8 years; mean Society of Thoracic Surgeons [STS] score, 4.9 [interquartile range, 3.3-7.6]), and had a secondary femoral access. The 30-day clinical outcomes were analyzed according to femoral access-site hemostasis (manual compression vs VCD), and according to the type of VCD (Perclose [Abbott Cardiovascular] vs Angio-Seal [Terumo Interventional Systems]) using a propensity-matched, multivariable, logistic regression model., Results: Manual compression was used in 941 patients (23.3%) and VCDs were used in 3090 patients (76.7%; Perclose in 1549 patients [38.4%] and Angio-Seal in 1541 patients [38.2%]) for secondary femoral access hemostasis. Vascular complications related to secondary access site occurred in 162 patients (4%), and were more frequent in patients who underwent manual compression (7.2%) compared with VCD hemostasis (3%; adjusted P<.001). In the VCD group, the use of Angio-Seal (vs Perclose) was associated with a higher rate of vascular complications (3.7% vs 2.4%, respectively; adjusted P=.02), femoral artery pseudoaneurysm (1.3% vs 0.4%, respectively; adjusted P<.01), invasive treatment requirement for treating vascular complications (surgery: 0.8% vs 0.3%, respectively [adjusted P=.03]; and thrombin injection: 0.9% vs 0%, respectively [adjusted P<.001])., Conclusion: VCDs represented a safer and more effective alternative compared with manual compression for secondary femoral access-site hemostasis in patients undergoing TAVR procedures, and the Perclose VCD was associated with the lowest risk of vascular complications. Future randomized studies are warranted.
- Published
- 2021
32. ST-Segment Elevation Myocardial Infarction Following Transcatheter Aortic Valve Replacement.
- Author
-
Faroux L, Lhermusier T, Vincent F, Nombela-Franco L, Tchétché D, Barbanti M, Abdel-Wahab M, Windecker S, Auffret V, Campanha-Borges DC, Fischer Q, Muñoz-Garcia E, Trillo-Nouche R, Jorgensen T, Serra V, Toggweiler S, Tarantini G, Saia F, Durand E, Donaint P, Gutierrez-Ibanes E, Wijeysundera HC, Veiga G, Patti G, D'Ascenzo F, Moreno R, Hengstenberg C, Chamandi C, Asmarats L, Hernandez-Antolin R, Gomez-Hospital JA, Cordoba-Soriano JG, Landes U, Jimenez-Diaz VA, Cruz-Gonzalez I, Nejjari M, Roubille F, Van Belle É, Armijo G, Siddiqui S, Costa G, Elsaify S, Pilgrim T, le Breton H, Urena M, Muñoz-Garcia AJ, Sondergaard L, Bach-Oller M, Fraccaro C, Eltchaninoff H, Metz D, Tamargo M, Fradejas-Sastre V, Rognoni A, Bruno F, Goliasch G, Santaló-Corcoy M, Jimenez-Mazuecos J, Webb JG, Muntané-Carol G, Paradis JM, Mangieri A, Ribeiro HB, Campelo-Parada F, and Rodés-Cabau J
- Subjects
- Aged, 80 and over, Coronary Angiography, Female, Follow-Up Studies, Global Health, Hospital Mortality trends, Humans, Incidence, Male, Percutaneous Coronary Intervention, Postoperative Complications epidemiology, Risk Factors, ST Elevation Myocardial Infarction diagnosis, ST Elevation Myocardial Infarction epidemiology, Time Factors, Aortic Valve Stenosis surgery, Postoperative Complications etiology, Risk Assessment methods, ST Elevation Myocardial Infarction etiology, Transcatheter Aortic Valve Replacement adverse effects
- Abstract
Background: Among patients with acute coronary syndrome following transcatheter aortic valve replacement (TAVR), those presenting with ST-segment elevation myocardial infarction (STEMI) are at highest risk., Objectives: The goal of this study was to determine the clinical characteristics, management, and outcomes of STEMI after TAVR., Methods: This was a multicenter study including 118 patients presenting with STEMI at a median of 255 days (interquartile range: 9 to 680 days) after TAVR. Procedural features of STEMI after TAVR managed with primary percutaneous coronary intervention (PCI) were compared with all-comer STEMI: 439 non-TAVR patients who had primary PCI within the 2 weeks before and after each post-TAVR STEMI case in 5 participating centers from different countries., Results: Median door-to-balloon time was higher in TAVR patients (40 min [interquartile range: 25 to 57 min] vs. 30 min [interquartile range: 25 to 35 min]; p = 0.003). Procedural time, fluoroscopy time, dose-area product, and contrast volume were also higher in TAVR patients (p < 0.01 for all). PCI failure occurred more frequently in patients with previous TAVR (16.5% vs. 3.9%; p < 0.001), including 5 patients in whom the culprit lesion was not revascularized owing to coronary ostia cannulation failure. In-hospital and late (median of 7 months [interquartile range: 1 to 21 months]) mortality rates were 25.4% and 42.4%, respectively (20.6% and 38.2% in primary PCI patients), and estimated glomerular filtration rate <60 ml/min (hazard ratio [HR]: 3.02; 95% confidence interval [CI]: 1.42 to 6.43; p = 0.004), Killip class ≥2 (HR: 2.74; 95% CI: 1.37 to 5.49; p = 0.004), and PCI failure (HR: 3.23; 95% CI: 1.42 to 7.31; p = 0.005) determined an increased risk., Conclusions: STEMI after TAVR was associated with very high in-hospital and mid-term mortality. Longer door-to-balloon times and a higher PCI failure rate were observed in TAVR patients, partially due to coronary access issues specific to the TAVR population, and this was associated with poorer outcomes., Competing Interests: Funding Support and Author Disclosures Dr. Faroux has received fellowship support from Institut Servier and the Association Régionale de Cardiologie de Champagne-Ardenne (ARCCA); and has received research grants from Biotronik, Edwards Lifesciences, and Medtronic. Dr. Abdel-Wahab has served as a consultant for Boston Scientific and Medtronic. Dr. Windecker has received research and educational grants from Abbott, Amgen, BMS, Bayer, Boston Scientific, Biotronik, Cardinal Health, CardioValve, CSL Behring, Daiichi-Sankyo, Edwards Lifesciences, Johnson & Johnson, Medtronic, Querbet, Polares, Sanofi, Terumo, and Sinomed. Dr. Auffret has received lecture fees from Edwards Lifesciences and Medtronic. Dr. Trillo-Nouche has served as a proctor for Boston Scientific and Medtronic. Dr. Toggweiler has served as a consultant and proctor for Abbott, Boston Scientific, Biosensors, and Medtronic. Dr. Tarantini has received lecture fees from Boston Scientific, Edwards Lifesciences, Gada, and Medtronic. Dr. Saia has served as a member of advisory boards for Abbott, Edwards Lifesciences, and Medtronic. Dr. Durand has served as a consultant for Edwards Lifesciences. Dr. Asmarats has served as a proctor for Abbott. Dr. Nejjari has served as a proctor for Abbott and Boston Scientific. Dr. Muntané-Carol was supported by a grant from the Fundación Alfonso Martín Escudero (Madrid, Spain). Dr. Mangieri has received an institutional grant from Boston Scientific. Dr. Rodés-Cabau has received institutional research grants from Edwards Lifesciences, Medtronic, and Boston Scientific; and holds the Research Chair “Fondation Famille Jacques Larivière” for the Development of Structural Heart Disease Interventions. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
33. Predictors and clinical impact of thrombosis after transcatheter mitral valve implantation using balloon-expandable bioprostheses.
- Author
-
Kikoïne J, Urena M, Chong Nguyen C, Fischer Q, Carrasco JL, Brochet E, Ducrocq G, Vahanian A, Iung B, and Himbert D
- Subjects
- Aortic Valve surgery, Echocardiography, Transesophageal, Humans, Male, Mitral Valve diagnostic imaging, Mitral Valve surgery, Prosthesis Design, Treatment Outcome, Aortic Valve Stenosis surgery, Bioprosthesis, Heart Valve Prosthesis adverse effects, Thrombosis diagnostic imaging, Thrombosis epidemiology, Thrombosis etiology, Transcatheter Aortic Valve Replacement
- Abstract
Aims: The aim of this study was to report the predictors and clinical impact of transcatheter heart valve (THV) thrombosis in patients undergoing transcatheter mitral valve implantation (TMVI)., Methods and Results: We included 130 patients who consecutively underwent TMVI. Transoesophageal echocardiography (TOE) and/or computed tomography (CT) were performed in 91.7% of patients at discharge, in 73.3% at three months and in 72% beyond three months. THV thrombosis was defined as the presence of at least one thickened leaflet with restricted motion confirmed by TOE or contrast CT and classified as immediate, early, or late according to the timing of diagnosis. THV thrombosis was observed in 16 (12.3%) patients: immediate in 43.7%, early in 37.5% and late in 18.8%. Most of these thromboses were subclinical (93.7%) and non-obstructive (87.5%). No thromboembolic event occurred. After optimisation of antithrombotic treatment, THV thromboses resolved in all but one patient. Predictors were shock for immediate (p<0.001), male sex for early (p=0.045) and absence of anticoagulation for both early (p=0.018) and late (p=0.023) THV thromboses., Conclusions: THV thrombosis is frequent after TMVI, occurs mainly within the first three months, is mostly subclinical and resolves after optimisation of antithrombotic treatment. An anticoagulation therapy for at least three months after the procedure is mandatory.
- Published
- 2021
- Full Text
- View/download PDF
34. Primary antiphospholipid syndrome revealed by acute myocardial infarction in young adults: a prospective observational study.
- Author
-
Chezel J, Fischer Q, Nicaise Roland P, Abtan J, Faille D, Van Gysel D, Papo T, Ducrocq G, and Sacre K
- Subjects
- Antibodies, Antiphospholipid, Humans, Prospective Studies, Young Adult, Antiphospholipid Syndrome complications, Antiphospholipid Syndrome diagnosis, Myocardial Infarction diagnosis
- Published
- 2021
- Full Text
- View/download PDF
35. Valve-in-Valve and Valve-in-Ring Transcatheter Mitral Valve Implantation in Young Women Contemplating Pregnancy.
- Author
-
Fuchs A, Urena M, Chong-Nguyen C, Kikoïne J, Brochet E, Abtan J, Fischer Q, Ducrocq G, Vahanian A, Iung B, and Himbert D
- Subjects
- Adult, Cardiac Catheterization, Female, Humans, Infant, Newborn, Mitral Valve surgery, Pregnancy, Prosthesis Design, Treatment Outcome, Young Adult, Bioprosthesis, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation, Mitral Valve Annuloplasty, Mitral Valve Insufficiency surgery
- Abstract
Background: Transcatheter mitral valve implantation (TMVI) is emerging as an alternative to surgical mitral valve replacement in selected high-risk patients. Delaying definitive mechanical mitral valve replacement and the constraints of anticoagulation thanks to TMVI may be an attractive option in young women contemplating pregnancy and suffering from failure of mitral bioprosthesis or annuloplasty. The aim of the study was to evaluate the possibility, safety, and outcomes of pregnancy after TMVI in this population., Methods: From 2013 to 2019, 12 young women contemplating pregnancy underwent transseptal valve-in-valve or valve-in-ring TMVI using the Edwards SAPIEN XT/3 valves and were prospectively followed up at 1 month, 6 months, 1 year, and yearly thereafter., Results: Mean age of the patients was 30±6 years. Bioprosthesis degeneration was observed in 7 cases and annuloplasty failure in 5. Three valve-in-ring patients required the implantation of a second valve, which led to an overall procedural success rate of 75%. One delayed left ventricular outflow tract obstruction required elective surgical mitral valve replacement. At 6 months/1 year, 83% of the patients were in New York Heart Association classes I/II. Mitral regurgitation was ≤2+ in all the cases and mean gradient was 7±2 mm Hg. Four patients could complete 6 full-term pregnancies. One symptomatic thrombosis occurred and resolved under aspirin and anticoagulation therapy. All others pregnancies were uneventful. Predelivery mean gradient was 11 mm Hg, and systolic pulmonary artery pressure was 32 mm Hg. There were 4 vaginal deliveries and 2 cesarians. Newborns were alive and healthy. At last follow-up, there was no death, and 3 patients required elective surgical mitral valve replacement at 6- to 54-month follow-up., Conclusions: Our study suggests that, in young women, transseptal TMVI to treat failing bioprostheses may result in good short-term outcomes that allow uneventful pregnancies. The results are less favorable in women with failed annuloplasty rings.
- Published
- 2020
- Full Text
- View/download PDF
36. Procedural Characteristics and Late Outcomes of Percutaneous Coronary Intervention in the Workup Pre-TAVR.
- Author
-
Faroux L, Campelo-Parada F, Munoz-Garcia E, Nombela-Franco L, Fischer Q, Donaint P, Serra V, Veiga G, Gutiérrez E, Vilalta V, Alperi A, Regueiro A, Asmarats L, Ribeiro HB, Matta A, Munoz-Garcia A, Armijo G, Urena M, Metz D, Rodenas-Alesina E, de la Torre Hernandez JM, Fernandez-Nofrerias E, Pascual I, Perez-Fuentes P, Arzamendi D, Campanha-Borges DC, Del Val D, Couture T, and Rodés-Cabau J
- Subjects
- Coronary Artery Bypass, Drug-Eluting Stents, Humans, Risk Factors, Treatment Outcome, Coronary Artery Disease surgery, Percutaneous Coronary Intervention, Transcatheter Aortic Valve Replacement
- Abstract
Objectives: This study sought to determine, in patients undergoing percutaneous coronary intervention (PCI) during the work-up pre-transcatheter aortic valve replacement (TAVR): 1) the clinical and peri-procedural PCI characteristics; 2) the long-term outcomes; and 3) the clinical events in those patients with complex coronary features., Background: A PCI is performed in about 25% of TAVR candidates, but procedural features and late outcomes of pre-TAVR PCI remain largely unknown., Methods: Multicenter study including 1197 consecutive patients who had PCI in the work-up pre-TAVR. A total of 1,705 lesions (1.5 ± 0.7 lesions per patient) were included. Death, stroke, myocardial infarction, and major adverse cardiovascular and cerebrovascular events (MACCE) were recorded, as well as target lesion failure (TLF) and target vessel failure (TVF)., Results: One-half of patients exhibited a multivessel disease and the mean SYNTAX (SYNergy between PCI with TAXUS and Cardiac Surgery) score was 12.1 ± 9.1. The lesions were of B2/C type, calcified, bifurcation, and ostial in 49.9%, 45.8%, 21.4%, and 19.3% of cases, respectively. After a median follow-up of 2 (interquartile range: 1 to 3) years, a total of 444 (37.1%) patients presented an MACCE. Forty patients exhibited TVF (3.3%), with TLF identified in 32 (2.7%) patients. By multivariable analysis, previous peripheral artery disease (p < 0.001), chronic obstructive pulmonary disease (p = 0.002), atrial fibrillation (p = 0.003), diabetes mellitus (p = 0.012), and incomplete revascularization (p = 0.014) determined an increased risk of MACCE. In patients with unprotected left main or SYNTAX score >32 (n = 128), TLF, TVF, and MACCE rates were 3.9%, 6.3%, and 35.9%, respectively (p = 0.378; p = 0.065, and p = 0.847, respectively, vs. the rest of the population)., Conclusions: Patients undergoing PCI in the work-up pre-TAVR frequently exhibited complex coronary lesions and multivessel disease. PCI was successful in most cases, and TLF and TVF rates at 2-year follow-up were low, also among patients with high-risk coronary features. However, overall MACCE occurred in about one-third of patients, with incomplete revascularization determining an increased risk. These results should inform future studies to better determine the optimal revascularization strategy pre-TAVR., Competing Interests: Author Relationship With Industry Dr. Faroux has received fellowship support from Institut Servier and the Association Régionale de Cardiologie de Champagne-Ardenne; and has received research grant support from Biotronik, Edwards Lifesciences, and Medtronic. Dr.Rodés-Cabau has received institutional research grants from Edwards Lifesciences, Medtronic, and Boston Scientific. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
37. Transcatheter aortic valve replacement in patients with paradoxical low-flow, low-gradient aortic stenosis: Incidence and predictors of treatment futility.
- Author
-
Freitas-Ferraz AB, Nombela-Franco L, Urena M, Maes F, Veiga G, Ribeiro H, Vilalta V, Silva I, Cheema AN, Islas F, Fischer Q, Fradejas-Sastre V, Rosa VEE, Fernandez-Nofrerias E, Moris C, Junquera L, Mohammadi S, Pibarot P, and Rodés-Cabau J
- Subjects
- Aged, Aged, 80 and over, Aortic Valve surgery, Female, Humans, Incidence, Male, Medical Futility, Risk Factors, Severity of Illness Index, Treatment Outcome, Aortic Valve Stenosis diagnostic imaging, Aortic Valve Stenosis epidemiology, Transcatheter Aortic Valve Replacement adverse effects
- Abstract
Background: Few and controversial data exist on the outcomes of patients with paradoxical low-flow, low-gradient aortic stenosis (PLFLG-AS) following transcatheter aortic valve replacement (TAVR). This study aims to better characterize clinical outcomes and predictors of treatment futility in PLFLG-AS patients undergoing TAVR., Methods: In this multicenter study, 318 patients with PLFLG-AS undergoing TAVR were categorized according to treatment futility, defined as all-cause mortality, poor functional status (NYHA class III-IV) or deterioration in functional class at 1-year follow-up. Clinical outcomes and the factors associated with treatment futility were assessed., Results: The mean age of the patients was 81.0 ± 8.3 years and 50.3% were women. At 1-year follow-up, 17.6% died and 12.9% had heart failure hospitalization. Residual impaired functional capacity (NYHA ≥ II) was present in 54.4% of patients who were alive at 1-year, and 9.8% remained in NYHA III/IV. The primary endpoint was observed in 103 (32.4%) patients, of which 54% died and 46% had a poor or worsening functional class. Factors independently associated with treatment futility were the presence of atrial fibrillation (AF) (OR:1.79, 95%CI, 1.04-3.10), chronic obstructive pulmonary disease (COPD) (OR:2.66, 95%CI, 1.50-4.74) and a lower SVi (OR per each decrease in 10 ml/m
2 :1.89, 95%CI, 1.06-3.45). The risk of treatment futility of patients with AF, COPD and a SVi < 30 ml/m2 was 66.38% (95%CI, 54.29%-78.48%)., Conclusion: Close to one-third of patients with PLFLG-AS failed to derive a benefit from TAVR. The presence of AF, COPD and a low SVi were predictors of treatment futility. Being able to identify patients less likely to improve after the procedure may help to guide management and improve outcomes in patients with PLFLG-AS., Competing Interests: Declaration of competing interest Dr. Rodés-Cabau has received institutional research grants from Edwards Lifesciencies, Medtronic and Boston Scientific. Dr. Pibarot reports having Core Lab contracts with Edwards Lifesciences for which he receives no direct compensation, and receiving grants from Edwards Lifesciences and Medtronic during the conduct of the study. The rest of authors do not report any potential conflict of interest with respect to the content of this study., (Copyright © 2020 Elsevier B.V. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
38. Outcomes of Transcatheter Aortic Valve Implantation in Patients Receiving Chronic Systemic Corticosteroid Treatment.
- Author
-
Gautier A, Urena M, Chong-Nguyen C, Fischer Q, Abtan J, Carrasco JL, Brochet E, Iung B, and Himbert D
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Time Factors, Treatment Outcome, Aortic Valve Stenosis surgery, Glucocorticoids therapeutic use, Prednisone therapeutic use, Transcatheter Aortic Valve Replacement
- Abstract
The aim of this study was to describe the effects of chronic systemic corticosteroid treatment (SCT) on early and late outcomes after transcatheter aortic valve implantation (TAVI). From October 2006 to November 2018, 1,299 patients underwent TAVI in our institution. Among them, 48 (3.7%) received chronic SCT at the time of procedure (SCT group). They were more frequently women (p = 0.08) and needed more often dialysis (p = 0.002). All other baseline characteristics were similar between both groups. At 30 days, there was no difference on mortality. However, after adjustment, the SCT group had more major vascular complications: 16.7% versus 7.4%, hazard ratio (HR) 2.52 (95% confidence interval [CI] 1.14 to 5.9, p = 0.023), major or life-threatening bleedings: 22.9% versus 12.4%, HR 2.02 (95% CI 1.00 to 4.08, p = 0.05), and tamponades: 8.3% versus 2.4%, HR 4.05 (95% CI 1.35 to 12.15, p <0.001) than the non-SCT group. One-year all-cause mortality was significantly higher in the SCT than in the non-SCT group (37.5% vs 12.5%, p <0.0001). Multivariate analysis confirmed that SCT use was an independent predictor of 1-year mortality (HR 2.29, 95% CI 1.16 to 4.50, p = 0.017). In conclusion, chronic use of SCT significantly increases the rates of early vascular complications, major or life-threatening bleedings and tamponade and is an independent predictor of 1-year all-cause mortality after TAVI., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
39. Case report of an isolated myocarditis due to COVID-19 infection in a paediatric patient.
- Author
-
Fischer Q, Brillat-Savarin N, Ducrocq G, and Ou P
- Abstract
Background: Cardiovascular complications of COVID-19 have been reported in the adult population including myocarditis. However, less is known about the myocardial involvement in paediatric patients., Case Summary: A 15-year-old boy was admitted to our intensive cardiac care unit with COVID-19 and an isolated acute myocarditis, confirmed on cardiac magnetic resonance imaging. No pulmonary lesion was observed on the chest CT scan. We report here the initial presentation, medical care, and clinical course of this patient., Discussion: In the context of the acute COVID-19 outbreak, screening for COVID-19 infection should be performed in children presenting with myocardial injury in an inflammatory context., (© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2020
- Full Text
- View/download PDF
40. Case report of anterior ST-elevation myocardial infarction in a patient with coronavirus disease-2019.
- Author
-
Fischer Q, Darmon A, Ducrocq G, and Feldman L
- Abstract
Background: Coronavirus disease-2019 (COVID-19) is an infectious disease appeared in China in December 2019 and, since then, has spread worldwide at a rapid pace., Case Summary: A patient with COVID-19 was hospitalized in our institution for a diabetic foot ulcer and presented afterwards a pulmonary oedema and concomitant anterior ST-segment elevation myocardial infarction. We report here on the initial presentation, coronary care and intervention, and clinical course of this patient., Discussion: Emergent percutaneous coronary intervention is feasible and safe in COVID-19 patients but requires a multidisciplinary effort involving caregivers from infectious disease, intensive care, and cardiology teams., (© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.)
- Published
- 2020
- Full Text
- View/download PDF
41. Transcatheter aortic valve replacement with the balloon-expandable SAPIEN 3 valve: Impact of calcium score on valve performance and clinical outcomes.
- Author
-
Guimarães L, Ferreira-Neto AN, Urena M, Nombela-Franco L, Wintzer-Wehekind J, Levesque MH, Himbert D, Fischer Q, Armijo G, Vera R, Kalavrouziotis D, and Rodés-Cabau J
- Subjects
- Aortic Valve diagnostic imaging, Aortic Valve surgery, Calcium, Humans, Prosthesis Design, Risk Factors, Severity of Illness Index, Treatment Outcome, Aortic Valve Insufficiency, Aortic Valve Stenosis diagnostic imaging, Aortic Valve Stenosis surgery, Heart Valve Prosthesis, Transcatheter Aortic Valve Replacement adverse effects
- Abstract
Background: Aortic valve calcification severity has been associated with higher rates of aortic regurgitation (AR) following TAVR, but scarce data exist on its impact with the use of newer generation transcatheter heart valves., Methods: This was a multicenter study including 626 patients with severe aortic stenosis who underwent TAVR with the SAPIEN 3 valve. Patients were divided in 2 groups according to the median index calcium score (iCS) for each sex: high CS (HCS, iCS ≥ median), and low iCS (LCS, iCS < median). Another analysis was performed in those patients with extreme iCS (ECS, iCS >75th percentile for each sex). Clinical and echocardiographic data were collected prospectively in a dedicated database., Results: The mean CS was 3758 ± 1417 AU and 1616 ± 691 AU in the HCS and LCS groups, respectively (p < 0.001). There were no differences between groups in 30-day mortality (HCS:2.6%, LCS:1.0%, p = 0.13) and stroke (HCS:2.6%,LCS:2.6%, p = 1.0) rates, but all cases (n = 5) of annulus rupture occurred in the HCS group (1.6% vs. 0%, p = 0.061). The incidence of moderate-severe AR post-TAVR was low in both groups (HCS:1.6%,LCS:1.6%, p = 1.0), and valve gradient and area were similar between groups. The results remained similar in the ECS group (mean CS:4607 ± 1424 AU), but a mildly increased mean transvalvular gradient post-TAVR was observed in ECS patients (12.1 ± 5.6 vs 11.0 ± 4.3 mmHg; p = 0.015)., Conclusion: Aortic valve calcification severity failed to impact mortality/stroke rates following TAVR with the SAPIEN 3 valve. Low rates of significant AR were observed irrespective of CS, and a mild increase in transvalvular gradient was observed in ECS patients., Competing Interests: Declaration of competing interest Dr. Rodés-Cabau has received institutional research grants from Edwards Lifesciences. The other authors have not reported any potential conflict of interest with respect to the content of this paper., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
42. Late Cerebrovascular Events Following Transcatheter Aortic Valve Replacement.
- Author
-
Muntané-Carol G, Urena M, Munoz-Garcia A, Padrón R, Gutiérrez E, Regueiro A, Serra V, Capretti G, Himbert D, Moris C, Sabaté M, Garcia Del Blanco B, Ferreira-Neto AN, Coté M, Fischer Q, Couture T, Kalavrouziotis D, and Rodés-Cabau J
- Subjects
- Aged, Aged, 80 and over, Aortic Valve Stenosis diagnostic imaging, Aortic Valve Stenosis mortality, Canada epidemiology, Cerebrovascular Disorders diagnostic imaging, Cerebrovascular Disorders mortality, Female, France epidemiology, Hospital Mortality, Humans, Incidence, Male, Retrospective Studies, Risk Factors, Spain epidemiology, Time Factors, Transcatheter Aortic Valve Replacement mortality, Treatment Outcome, Aortic Valve Stenosis surgery, Cerebrovascular Disorders epidemiology, Transcatheter Aortic Valve Replacement adverse effects
- Abstract
Objectives: This study sought to determine the incidence, clinical characteristics, associated factors, and outcomes of late cerebrovascular events (LCVEs) (>30 days post-procedure) following transcatheter aortic valve replacement (TAVR)., Background: Scarce data exist on LCVEs following TAVR., Methods: This was a multicenter study including 3,750 consecutive patients (mean age, 80 ± 8 years; 50.5% of women) who underwent TAVR and survived beyond 30 days. LCVEs were defined according to the Valve Academic Research Consortium 2 (VARC 2) criteria., Results: LCVEs occurred in 192 (5.1%) patients (stroke, 80.2%; transient ischemic attack, 19.8%) after a median follow-up of 2 (1 to 4) years. Late stroke was of ischemic, hemorrhagic, and undetermined origin in 80.5%, 18.8%, and 0.7% of patients, respectively. Older age, previous cerebrovascular disease, higher mean aortic gradient at baseline, the occurrence of stroke during the periprocedural TAVR period, and the lack of anticoagulation (novel oral anticoagulants or vitamin K antagonists) post-TAVR were independent factors associated with late ischemic stroke/transient ischemic attack (p < 0.05 for all). Echocardiographic data at the time of the LCVE showed no signs of valve thrombosis or degeneration in the vast majority (97%) patients. Late stroke was disabling in 107 (69.5%) patients (ischemic, 68%; hemorrhagic, 79%), and associated with an in-hospital mortality rate of 29.2%., Conclusions: LCVEs occurred in 5.1% of TAVR recipients after a median follow-up of 2 years. LCVEs were ischemic in most cases, with older age, previous cerebrovascular events, higher mean aortic gradient at baseline, the occurrence during the periprocedural TAVR period, and lack of anticoagulation (but not valve thrombosis/degeneration) determining an increased risk. Late stroke was disabling in most cases and associated with dreadful early and midterm outcomes., (Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
43. Comparison of Transfemoral Versus Transradial Secondary Access in Transcatheter Aortic Valve Replacement.
- Author
-
Junquera L, Urena M, Latib A, Muñoz-Garcia A, Nombela-Franco L, Faurie B, Veiga-Fernandez G, Alperi A, Serra V, Regueiro A, Fischer Q, Himbert D, Mangieri A, Colombo A, Muñoz-García E, Vera-Urquiza R, Jiménez-Quevedo P, de la Torre JM, Pascual I, Garcia Del Blanco B, Sabaté M, Mohammadi S, Freitas-Ferraz AB, Guimarães L, Couture T, Côté M, and Rodés-Cabau J
- Subjects
- Aged, Aged, 80 and over, Canada, Catheterization, Peripheral adverse effects, Catheterization, Peripheral mortality, Databases, Factual, Europe, Female, Humans, Male, Postoperative Complications etiology, Postoperative Complications mortality, Punctures, Retrospective Studies, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, Catheterization, Peripheral methods, Femoral Artery, Radial Artery, Transcatheter Aortic Valve Replacement adverse effects, Transcatheter Aortic Valve Replacement mortality
- Abstract
Background: Transfemoral approach has been commonly used as secondary access in transcatheter aortic valve replacement (TAVR). Scarce data exist on the use and potential clinical benefits of the transradial approach as secondary access during TAVR procedures. The objective of the study is to determine the occurrence of vascular complications (VC) and clinical outcomes according to secondary access (transfemoral versus transradial) in patients undergoing TAVR., Methods: This was a multicenter study including 4949 patients who underwent TAVR (mean age, 81±8 years, mean Society of Thoracic Surgeons score, 4.9 [3.3-7.5]). Transfemoral and transradial approaches were used as secondary access in 4016 (81.1%) and 933 (18.9%) patients, respectively. The 30-day clinical events (vascular and bleeding complications, stroke, acute kidney injury, and mortality) were evaluated and defined according to Valve Academic Research Consortium-2 criteria. Clinical outcomes were analyzed according to the secondary access (transfemoral versus transradial) in the overall population and in a propensity score-matched population involving 2978 transfemoral and 928 transradial patients., Results: Related-access VC occurred in 834 (16.9%) patients (major VC, 5.7%) and were related to the secondary access in 172 (3.5%) patients (major VC, 1.3%). The rate of VC related to the secondary access was higher in the transfemoral group (VC, 4.1% versus 0.9%, P <0.001; major VC, 1.6% versus 0%, P <0.001). In the propensity score-matched population, VC related to the secondary access remained higher in the transfemoral group (4.7% versus 0.9%, P <0.001; major VC, 1.8% versus 0%, P <0.001), which also exhibited a higher rate of major/life-threatening bleeding events (1.0% versus 0%, P <0.001). Significant differences between secondary access groups were observed regarding the rates of 30-day stroke (transfemoral: 3.1%, transradial: 1.6%; P =0.043), acute kidney injury (transfemoral: 9.9%, transradial: 5.7%; P <0.001), and mortality (transfemoral: 4.0%, transradial: 2.4%, P =0.047)., Conclusions: The use of transradial approach as secondary access in TAVR procedures was associated with a significant reduction in vascular and bleeding complications and improved 30-day outcomes. Future randomized studies are warranted.
- Published
- 2020
- Full Text
- View/download PDF
44. Late Electrocardiographic Changes in Patients With New-Onset Left Bundle Branch Block Following Transcatheter Aortic Valve Implantation.
- Author
-
Faroux L, Muntané-Carol G, Urena M, Nombela-Franco L, Amat-Santos I, Kleiman N, Munoz-Garcia A, Atienza F, Serra V, Deyell MW, Veiga-Fernandez G, Masson JB, Canadas-Godoy V, Himbert D, Fischer Q, Castrodeza J, Elizaga J, Pascual JF, Webb JG, de la Torre JM, Asmarats L, Pelletier-Beaumont E, Alméndarez M, Couture T, Philippon F, and Rodes-Cabau J
- Subjects
- Aged, Aged, 80 and over, Atrial Fibrillation epidemiology, Bundle-Branch Block epidemiology, Bundle-Branch Block therapy, Comorbidity, Female, Humans, Incidence, Male, Pacemaker, Artificial, Postoperative Complications epidemiology, Postoperative Complications therapy, Aortic Valve surgery, Bundle-Branch Block physiopathology, Cardiac Pacing, Artificial, Electrocardiography, Postoperative Complications physiopathology, Recovery of Function, Transcatheter Aortic Valve Replacement
- Abstract
This study sought to determine, in patients with new-onset persistent left bundle branch block (NOP-LBBB) after transcatheter aortic valve implantation (TAVI), the incidence and factors associated with (i) LBBB recovery and (ii) permanent pacemaker implantation (PPI) at 1-year follow-up. This was a multicenter study including 153 patients (mean age: 81 ± 5 years, 56% of women) with NOP-LBBB post-TAVI (balloon-expandable valve in 112 patients). Delta PR (ΔPR) and delta QRS (ΔQRS) were defined as the difference in PR and QRS length between baseline and hospital discharge ECG, and the relative ΔPR and ΔQRS as absolute ΔPR and ΔQRS divided by baseline PR and QRS length, respectively. The patients had a clinical visit and 12-lead ECG at 1-year follow-up. LBBB recovery was observed in 50 patients (33%), and 14 patients (9%) had advanced conduction disturbances requiring PPI during the follow-up period. No clinical or ECG variables were associated with LBBB recovery, including prosthesis type (self- or balloon-expandable valve, p = 0.563), QRS width at baseline/discharge or absolute/relative ΔQRS (p >0.10 for all). The presence of atrial fibrillation at baseline (0.026), a longer PR interval at discharge (0.009), and a longer absolute and relative ΔPR (p = 0.002 and p = 0.004, respectively) were associated with an increased risk of PPI at 1-year follow-up. In conclusion, NOP-LBBB post-TAVI resolved in one-third of patients at 1-year follow-up, but no clinical or ECG variables were associated with LBBB recovery. Conversely, a nonsinus rhythm at baseline and a longer ΔPR were associated with an increased risk of PPI within the year after TAVI., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
45. Acute Coronary Syndrome Following Transcatheter Aortic Valve Replacement.
- Author
-
Faroux L, Munoz-Garcia E, Serra V, Alperi A, Nombela-Franco L, Fischer Q, Veiga G, Donaint P, Asmarats L, Vilalta V, Chamandi C, Regueiro A, Gutiérrez E, Munoz-Garcia A, Garcia Del Blanco B, Bach-Oller M, Moris C, Armijo G, Urena M, Fradejas-Sastre V, Metz D, Castillo P, Fernandez-Nofrerias E, Sabaté M, Tamargo M, Del Val D, Couture T, and Rodes-Cabau J
- Subjects
- Acute Coronary Syndrome diagnosis, Acute Coronary Syndrome mortality, Acute Coronary Syndrome therapy, Aged, Aged, 80 and over, Angina, Unstable diagnosis, Angina, Unstable mortality, Angina, Unstable therapy, Female, Hospital Mortality, Humans, Incidence, Male, Non-ST Elevated Myocardial Infarction diagnosis, Non-ST Elevated Myocardial Infarction mortality, Non-ST Elevated Myocardial Infarction therapy, Percutaneous Coronary Intervention, Risk Assessment, Risk Factors, ST Elevation Myocardial Infarction diagnosis, ST Elevation Myocardial Infarction mortality, ST Elevation Myocardial Infarction therapy, Spain epidemiology, Time Factors, Transcatheter Aortic Valve Replacement mortality, Treatment Outcome, Acute Coronary Syndrome epidemiology, Angina, Unstable epidemiology, Non-ST Elevated Myocardial Infarction epidemiology, ST Elevation Myocardial Infarction epidemiology, Transcatheter Aortic Valve Replacement adverse effects
- Abstract
Background: Scarce data exist on coronary events following transcatheter aortic valve replacement (TAVR), and no study has determined the factors associated with poorer outcomes in this setting. This study sought to determine the clinical characteristics, outcomes, and prognostic factors of acute coronary syndrome (ACS) events following TAVR., Methods: Multicenter cohort study including a total of 270 patients presenting an ACS after a median time of 12 (interquartile range, 5-17) months post-TAVR. Post-ACS death, myocardial infarction, stroke, and overall major adverse cardiovascular or cerebrovascular events were recorded., Results: The ACS clinical presentation consisted of non-ST-segment-elevation myocardial infarction (STEMI) type 2 (31.9%), non-STEMI type 1 (31.5%), unstable angina (28.5%), and STEMI (8.1%). An invasive strategy was used in 163 patients (60.4%), and a percutaneous coronary intervention was performed in 97 patients (35.9%). Coronary access issues were observed in 2.5% and 2.1% of coronary angiography and percutaneous coronary intervention procedures, respectively. The in-hospital mortality rate was 10.0%, and at a median follow-up of 17 (interquartile range, 5-32) months, the rates of death, stroke, myocardial infarction, and major adverse cardiovascular or cerebrovascular events were 43.0%, 4.1%, 15.2%, and 52.6%, respectively. By multivariable analysis, revascularization at ACS time was associated with a reduction of the risk of all-cause death (hazard ratio, 0.54 [95% CI, 0.36-0.81] P =0.003), whereas STEMI increased the risk of all-cause death (hazard ratio, 2.06 [95% CI, 1.05-4.03] P =0.036) and major adverse cardiovascular or cerebrovascular events (hazard ratio, 1.97 [95% CI, 1.08-3.57] P =0.026)., Conclusions: ACS events in TAVR recipients exhibited specific characteristics (ACS presentation, low use of invasive procedures, coronary access issues) and were associated with a poor prognosis, with a very high in-hospital and late death rate. STEMI and the lack of coronary revascularization determined an increased risk. These results should inform future studies to improve both the prevention and management of ACS post-TAVR.
- Published
- 2020
- Full Text
- View/download PDF
46. Performing optimal transcatheter aortic valve implantation: The need for tailored use of transcatheter valves.
- Author
-
Fischer Q, Urena M, Bouleti C, Abtan J, Brochet E, Carrasco JL, Iung B, Vahanian A, and Himbert D
- Subjects
- Aged, Aged, 80 and over, Aortic Valve diagnostic imaging, Aortic Valve physiopathology, Aortic Valve Stenosis diagnostic imaging, Aortic Valve Stenosis mortality, Aortic Valve Stenosis physiopathology, Clinical Decision-Making, Female, Humans, Male, Patient Selection, Postoperative Complications etiology, Recovery of Function, Time Factors, Transcatheter Aortic Valve Replacement adverse effects, Transcatheter Aortic Valve Replacement mortality, Treatment Outcome, Aortic Valve surgery, Aortic Valve Stenosis surgery, Balloon Valvuloplasty, Heart Valve Prosthesis, Prosthesis Design, Transcatheter Aortic Valve Replacement instrumentation
- Abstract
Background: Despite the worldwide development of transcatheter aortic valve implantation (TAVI) over the last decade, strategies that take patient characteristics into account to guide the choice of transcatheter heart valve have not been evaluated., Aim: To evaluate the immediate results of TAVI using a tailored choice of balloon-expandable or self-expanding transcatheter heart valve, according to each patient's clinical and anatomical characteristics., Methods: This single-centre observational study included all patients treated with TAVI from 2012 to 2017. The 30-day results were reported according to Valve Academic Research Consortium-2 criteria. A total of 502 patients were included (mean age, 81±9 years; 52% men; mean EuroSCORE II, 7.0±6.5%). Three main variables guided the choice of transcatheter heart valve: the anatomy of the iliofemoral arteries and of the aortic root, and the general condition of the patient., Results: A SAPIEN™ balloon-expandable transcatheter heart valve was used in 275 patients (55%) and a CoreValve™ self-expanding transcatheter heart valve in 227 patients (45%). The approach was transfemoral in 427 patients (85%), and only 29 patients (6%) required transthoracic access. At 30-day follow-up, the rates of adverse events were as follows: mortality, 3.2%; stroke, 3.0%; major bleeding, 5.9%; and major vascular complications, 6.0%. Rates of complications at 30 days were similar in the SAPIEN™ and CoreValve™ groups, except for a higher rate of pacemaker implantation in the latter group (29.5% vs. 14.5%; P<0.001)., Conclusion: The choice of balloon-expandable or self-expanding transcatheter heart valve tailored to the patient's clinical and anatomical characteristics allows for maximal use of the transfemoral approach, and is associated with low 30-day rates of major complications and mortality., (Copyright © 2019 Elsevier Masson SAS. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
47. Impact of moderate to severe mitral stenosis in patients undergoing transcatheter aortic valve replacement.
- Author
-
Fischer Q, Himbert D, Bernier M, Urena M, Nunes Ferreira-Neto A, Paradis JM, Mohammadi S, Iung B, and Rodés-Cabau J
- Subjects
- Aged, Aged, 80 and over, Aortic Valve Stenosis diagnosis, Aortic Valve Stenosis epidemiology, Comorbidity, Female, France epidemiology, Humans, Male, Mitral Valve Stenosis epidemiology, Mitral Valve Stenosis surgery, Retrospective Studies, Risk Factors, Severity of Illness Index, Aortic Valve surgery, Aortic Valve Stenosis surgery, Echocardiography methods, Mitral Valve diagnostic imaging, Mitral Valve Stenosis diagnosis, Transcatheter Aortic Valve Replacement methods
- Abstract
Objective: In patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR), the impact of concomitant mitral stenosis (MS) remains unknown. The aim of this study was to determine the incidence and impact of moderate to severe MS in patients undergoing TAVR., Methods: The study included 2113 consecutive patients (mean age: 80 ± 9 years, mean STS: 6.4 ± 5.2%) who underwent TAVR in 2 centers. The presence of MS was defined as a mean transmitral gradient ≥ 5 mm Hg on baseline echocardiography in the absence of severe mitral regurgitation. Clinical events were prospectively collected in a dedicated TAVR database., Results: A total of 157 patients (7.4%) had moderate to severe MS (mean gradient: 7.2 ± 2.8 mm Hg; degenerative origin in 88%). Patients with MS were younger, more frequently women, had a higher left ventricular ejection fraction and an increased rate of severe pulmonary hypertension (p < 0.02 for all). Thirty-day mortality was similar in both groups (MS: 3.8%; no MS: 5.5%, adjusted p = 0.34). At a mean follow-up of 3 ± 2 years, there were no differences between groups in mortality (MS: 35%, no MS: 36.2%, adjusted HR: 1.14, 95% CI: 0.86-1.51), or heart failure rehospitalization (MS: 21%, no MS: 21.7%; adjusted HR: 1.16, 95% CI: 0.81-1.67). Patients with MS exhibited a similar functional status at follow-up compared to those with no MS (NYHA I-II in 85% and 88% of patients, respectively, adjusted p = 0.20)., Conclusions: About 7% of patients undergoing TAVR had concomitant moderate to severe MS. The presence of MS had no negative impact on early and mid-term clinical outcomes post-TAVR. These results suggest that TAVR is a valid alternative for treating patients with aortic stenosis in the presence of moderate to severe MS., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
48. Transcatheter aortic valve replacement: relative safety and efficacy of the procedure with different devices.
- Author
-
Del Val D, Ferreira-Neto AN, Asmarats L, Maes F, Guimaraes L, Junquera L, Wintzer J, Fischer Q, Barroso de Freitas Ferraz A, Puri R, and Rodés-Cabau J
- Subjects
- Heart Valve Prosthesis adverse effects, Humans, Kaplan-Meier Estimate, Treatment Outcome, Aortic Valve surgery, Transcatheter Aortic Valve Replacement adverse effects, Transcatheter Aortic Valve Replacement instrumentation
- Abstract
Introduction: Transcatheter aortic valve replacement (TAVR) is a well-established treatment for patients with severe aortic stenosis and intermediate-to-high surgical risk. The increasing clinical experience along with technical and design iterations of transcatheter valve systems have contributed to reducing adverse events and improving clinical outcomes., Areas Covered: Overview of the latest generation transcatheter heart valves (THVs), focusing on early safety and efficacy outcomes., Expert Commentary: Improvements in valve repositionability, reducing the size of valve delivery systems, and antiparavalvular leak iterations have contributed to improving the safety and clinical outcomes following TAVR. However, while certain complications like major vascular events and residual paravalvular leaks have significantly decreased with the arrival of newer generation THVs, no major changes in thromboembolic events (particularly stroke) have been observed, whereas other complications like conduction disturbances requiring pacemaker implantation have slightly increased over time. Also, no major progress on device retrievability has been observed in the last years. The expansion of TAVR toward the treatment of younger and lower risk patients, as well as newer indications (e.g. asymptomatic patients) will likely require an extra-effort involving additional device iterations and complementary therapies (e.g. embolic protection, newer vascular closure devices) to further improve safety and clinical outcomes.
- Published
- 2019
- Full Text
- View/download PDF
49. Impact of Preexisting Left Bundle Branch Block in Transcatheter Aortic Valve Replacement Recipients.
- Author
-
Fischer Q, Himbert D, Webb JG, Eltchaninoff H, Muñoz-García AJ, Tamburino C, Nombela-Franco L, Nietlispach F, Moris C, Ruel M, Dager AE, Serra V, Cheema AN, Amat-Santos IJ, de Brito FS, Ribeiro H, Abizaid A, Sarmento-Leite R, Dumont E, Barbanti M, Durand E, Alonso Briales JH, Bouleti C, Immè S, Maisano F, Del Valle R, Miguel Benitez L, García Del Blanco B, Côté M, Philippon F, Urena M, and Rodés-Cabau J
- Subjects
- Aged, Aged, 80 and over, Aortic Valve diagnostic imaging, Aortic Valve physiopathology, Brazil epidemiology, Bundle-Branch Block diagnosis, Bundle-Branch Block mortality, Bundle-Branch Block physiopathology, Canada epidemiology, Echocardiography, Electrocardiography, Europe epidemiology, Female, Heart Valve Diseases diagnostic imaging, Heart Valve Diseases mortality, Heart Valve Diseases physiopathology, Humans, Male, Pacemaker, Artificial, Postoperative Complications mortality, Postoperative Complications therapy, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, Aortic Valve surgery, Bundle-Branch Block therapy, Cardiac Pacing, Artificial adverse effects, Cardiac Pacing, Artificial mortality, Heart Valve Diseases surgery, Transcatheter Aortic Valve Replacement adverse effects, Transcatheter Aortic Valve Replacement mortality
- Abstract
Background: The impact of preexisting left bundle branch block (LBBB) in transcatheter aortic valve replacement (TAVR) recipients is unknown. The aim of this study was to determine the impact of preexisting LBBB on clinical outcomes after TAVR., Methods and Results: This multicenter study evaluated 3404 TAVR candidates according to the presence or absence of LBBB on baseline ECG. TAVR complications and causes of death were defined according to Valve Academic Research Consortium-2 definitions. Follow-up outpatient visits or telephone interviews were conducted at 30 days, 12 months, and yearly thereafter. Echocardiography examinations were performed at baseline, at hospital discharge, and at 1-year follow-up. Preexisting LBBB was present in 398 patients (11.7%) and was associated with an increased risk of permanent pacemaker implantation (PPI; 21.1% versus 14.8%; adjusted odds ratio, 1.51; 95% CI, 1.12-2.04) but not death (7.3% versus 5.5%; adjusted odds ratio, 1.33; 95% CI, 0.84-2.12) at 30 days. At a mean follow-up of 22±21 months, there were no differences between patients with and without preexisting LBBB in overall mortality (adjusted hazard ratio, 0.94; 95% CI, 0.75-1.18) and cardiovascular mortality (adjusted hazard ratio, 0.90; 95% CI, 0.68-1.21). In a subanalysis of 2421 patients without PPI at 30 days and with complete follow-up about the PPI, preexisting LBBB was not associated with an increased risk of PPI or sudden cardiac death. Patients with preexisting LBBB had a lower left ventricular ejection fraction (LVEF) at baseline and at 1-year follow-up ( P <0.001 for both), but those with low LVEF exhibited a similar increase in LVEF over time after TAVR compared with patients with no preexisting LBBB ( P=0.327)., Conclusions: Preexisting LBBB significantly increased the risk of early (but not late) PPI after TAVR, without any significant effect on overall mortality or cardiovascular mortality. Preexisting LBBB was associated with lower LVEF pre-TAVR but did not prevent an increase in LVEF post-TAVR similar to patients without LBBB.
- Published
- 2018
- Full Text
- View/download PDF
50. Liberal Right Ventricular Assist Device Extracorporeal Membrane Oxygenation Support for Right Ventricular Failure after Implantable Left Ventricular Assist Device Placement.
- Author
-
Fischer Q and Kirsch M
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, Treatment Outcome, Ventricular Dysfunction, Right mortality, Extracorporeal Membrane Oxygenation methods, Heart-Assist Devices adverse effects, Ventricular Dysfunction, Right etiology, Ventricular Dysfunction, Right therapy
- Abstract
Refractory right ventricular failure (RVF) after implantation of left ventricular assist device (LVAD) is a dramatic complication. The addition of right ventricular assist device (RVAD) may improve RV recovery and lead to improve outcomes. From February 2012 to September 2014, 44 patients received a HeartMate II. These patients were retrospectively compared in two groups according to early liberal implantation of an extracorporeal membrane oxygenation (ECMO) used as a RVAD established between a femoral vein and the pulmonary artery. Of the 44 patients, 22 required addition of a temporary RVAD (t-RVAD group). Patients are sicker in the t-RVAD group with significantly higher rate of preoperative extracorporeal life support (46% vs. 9%; p = 0.016) or any mechanical circulatory support (55% vs. 14%; p = 0.01), more preoperative hemofiltration (23% vs. 0%; p = 0.048), and more inotrope support by dobutamine (68.2% vs. 27.3%; p = 0.015). Likewise Michigan risk score was significantly higher in t-RVAD group (2.61 ± 2.2 vs. 1.0 ± 1.6 pts; p = 0.013) and INTERMACS clinical profile (2.1 ± 0.6 vs. 3.4 ± 1.3 pts; p = 0.0001). Despite severity of preimplant conditions in t-RVAD group, clinical outcomes did not differ in both groups with similar survival rate at 6 months (60.4 ± 12 vs. 71.4 ± 9.9%; p = 0.585). Early and liberal use of temporary RVAD in patients with risk factors of RVF could improve the prognostic after LVAD implantation.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.